NEWTON, Mass., July 24 /PRNewswire/ -- Aspect Medical Systems, Inc.
(Nasdaq: ASPM), the world's leading provider of consciousness monitoring
technology, has named Ralph Germscheid vice president of sales, announced
Nassib Chamoun, president and CEO of Aspect. Germscheid brings more than 20
years of sales and sales management experience in the anesthesia market. He
joined Nellcor (acquired by Mallinckrodt in 1998) more than 16 years ago, and
began shortly after the company's introduction of pulse oximetry into the
anesthesia market. He will be responsible for directing Aspect's sales and
distribution organization to expand market penetration of the company's
proprietary BIS monitoring system.
( Photo: http://www.newscom.com/cgi-bin/prnh/20000405/ASPMLOGO )
"Ralph brings a strong record of success in conceptual selling of new
technologies to the anesthesia community," said Chamoun. "His role in
developing the market for pulse oximetry and helping to establish the
technology as a standard of care in anesthesia is directly applicable to
Aspect's mission. Moreover, Ralph's charismatic style and proven leadership
position him well to quickly become an integral part of our organization and
further increase the size and scope of our presence in the marketplace."
Germscheid joins Aspect with a track record of exceeding sales objectives
at Nellcor, Nellcor Puritan Bennett and Mallinckrodt. For the past two years,
he served as vice president of sales for Mallinckrodt's alternate care
business managing a large team of sales representatives, as well as corporate
accounts and customer service. In this position, Germscheid spearheaded
programs to integrate and expand the organization, such as the design and
implementation of a strategic sales information system. In addition, he
established a national network of independent manufacturers representatives to
expand product availability for customers. Prior to Mallinckrodt's
acquisition of Nellcor Puritan Bennett, Germscheid was western area sales
manager responsible for sales and clinical personnel in 26 states.
"Aspect is an innovative company with an energetic spirit and a technology
that truly makes a difference in patient care," Germscheid stated. "I look
forward to leading and empowering the field sales organization to accelerate
the market penetration of BIS technology and further improve anesthesia
About BIS Monitoring
Developed in collaboration with leading anesthesiologists, BIS monitoring
enables clinicians to assess and manage the effects of drug dosing in the
operating room and intensive care settings.
BIS monitoring uses a sensor placed on the forehead to capture EEG
signals, which are translated into a single number ranging from 100 (for wide
awake) to zero (indicating the absence of brain electrical activity). As a
result, BIS monitoring allows clinicians to better determine the amount of
drug that each patient needs, thereby helping to prevent over-dosing and
under-dosing. In the OR, this enables patients to have a faster and higher
quality recovery with fewer post-operative side effects. These benefits are
achieved while the provider is able to continuously assess the risk of patient
awareness during surgery. In critical care settings, BIS monitoring is used
to titrate sedatives and help minimize the clinical and economic consequences
of under-sedation and over-sedation.
BIS technology is available in Aspect's A-2000(TM) BIS monitor and has
been licensed for integration into the majority of patient monitoring and
anesthesia delivery systems, including Agilent Technologies, Drager, GE
Marquette, Nihon Kohden and Spacelabs Medical.
Since its commercial introduction in October 1996, more than 900
healthcare facilities nationwide have adopted the BIS monitor, with more than
8,200 monitors in use and over 1,800,000 patients monitored across the globe.
To date, more than 450 peer-reviewed articles and abstracts have been
published that document the efficacy, limitations and outcomes benefits of the
About Aspect Medical Systems, Inc.
Aspect Medical Systems, Inc. develops noninvasive monitoring systems to
improve the cost effectiveness and quality of patient care. The company's
systems utilize innovative, patented, digital signal processing software
linked to proprietary sensors. Aspect meets ISO 9001 certification
requirements. For more information, visit the company's Web site at
Certain statements in this release are forward looking and may involve
risk and uncertainties, including statements with respect to market acceptance
and market penetration. Among the factors that could cause actual results to
differ materially from those indicated by such forward-looking statements are
the results of clinical trials, the Company's ability to successfully
commercialize its products and products under development, the company's
ability to achieve and maintain regulatory approval of products under
development, the scope of the company's patent protection and other risks
included under the heading "Risk Factors" in the company's Quarterly Report on
Form 10-Q filed on May 15, 2000, filed with the Securities and Exchange
Bispectral Index and BIS are registered trademarks of Aspect Medical
Systems, Inc. A-2000 is a trademark of Aspect Medical Systems, Inc.
Contact: Lorie Fiber/Courtney Walker
Fischer & Partners, Inc.
310-577-7870 ext. 109/113
SOURCE Aspect Medical Systems, Inc.